ES2241830T3 - Composiciones farmaceuticas que comprenden un enantiomero de quinolina condensado en posicion 1,2 inhibidor de la farnesil-transferasa. - Google Patents

Composiciones farmaceuticas que comprenden un enantiomero de quinolina condensado en posicion 1,2 inhibidor de la farnesil-transferasa.

Info

Publication number
ES2241830T3
ES2241830T3 ES01938263T ES01938263T ES2241830T3 ES 2241830 T3 ES2241830 T3 ES 2241830T3 ES 01938263 T ES01938263 T ES 01938263T ES 01938263 T ES01938263 T ES 01938263T ES 2241830 T3 ES2241830 T3 ES 2241830T3
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
chlorophenyl
pharmaceutical composition
active ingredient
quinazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01938263T
Other languages
English (en)
Spanish (es)
Inventor
Marc Gaston Janssen-Cilag S.A. VENET
Patrick Rene Janssen-Cilag S.A. Angibaud
David William Janssen Pharmaceutica Inc. END
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2241830T3 publication Critical patent/ES2241830T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES01938263T 2000-06-22 2001-06-13 Composiciones farmaceuticas que comprenden un enantiomero de quinolina condensado en posicion 1,2 inhibidor de la farnesil-transferasa. Expired - Lifetime ES2241830T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
EP00202181 2000-06-22

Publications (1)

Publication Number Publication Date
ES2241830T3 true ES2241830T3 (es) 2005-11-01

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01938263T Expired - Lifetime ES2241830T3 (es) 2000-06-22 2001-06-13 Composiciones farmaceuticas que comprenden un enantiomero de quinolina condensado en posicion 1,2 inhibidor de la farnesil-transferasa.

Country Status (33)

Country Link
US (3) US20030114471A1 (https=)
EP (1) EP1296984B1 (https=)
JP (1) JP4919575B2 (https=)
KR (2) KR100846370B1 (https=)
CN (1) CN1207296C (https=)
AR (1) AR030704A1 (https=)
AT (1) ATE294804T1 (https=)
AU (3) AU2001263962B2 (https=)
BG (1) BG65894B1 (https=)
BR (1) BRPI0111743B8 (https=)
CA (1) CA2410232C (https=)
CZ (1) CZ295278B6 (https=)
DE (1) DE60110592T2 (https=)
EA (1) EA005065B1 (https=)
EE (1) EE04966B1 (https=)
EG (1) EG24180A (https=)
ES (1) ES2241830T3 (https=)
HR (1) HRP20020989B1 (https=)
HU (1) HU229095B1 (https=)
IL (2) IL153560A0 (https=)
IS (1) IS2596B (https=)
JO (1) JO2361B1 (https=)
MX (1) MXPA02012845A (https=)
MY (1) MY127734A (https=)
NO (1) NO324494B1 (https=)
NZ (1) NZ522481A (https=)
PA (1) PA8519501A1 (https=)
PL (1) PL209521B1 (https=)
SA (1) SA01220349B1 (https=)
SK (1) SK285699B6 (https=)
UA (1) UA73572C2 (https=)
WO (1) WO2001098302A1 (https=)
ZA (1) ZA200210305B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
DE60307616T2 (de) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016172342A1 (en) 2015-04-21 2016-10-27 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
HUE044698T2 (hu) 2015-08-17 2019-11-28 Kura Oncology Inc Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
JP2000507955A (ja) 1996-04-03 2000-06-27 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
RU2205831C2 (ru) * 1997-04-25 2003-06-10 Янссен Фармацевтика Н.В. Хиназолиноны, ингибирующие фарнезилтрансферазу
CN100525766C (zh) 1997-06-02 2009-08-12 詹森药业有限公司 用作平滑肌细胞增殖抑制剂的（咪唑-5-基）甲基-2-喹啉酮衍生物
PL193464B1 (pl) * 1998-07-06 2007-02-28 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
TR200101343T2 (tr) * 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
DE69923849T2 (de) * 1998-08-27 2006-01-12 Pfizer Products Inc., Groton Quinolin-2-on-derivate verwendbar als antikrebsmittel
DK1140935T3 (da) * 1998-12-23 2003-09-01 Janssen Pharmaceutica Nv 1,2-anellerede quinolinderivater
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
SK11002001A3 (sk) * 1999-02-11 2002-05-09 Pfizer Products Inc. Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
ATE375794T1 (de) * 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives

Also Published As

Publication number Publication date
IS6590A (is) 2002-10-25
HUP0300872A2 (hu) 2003-07-28
HK1058363A1 (en) 2004-05-14
BR0111743A (pt) 2003-07-08
EP1296984B1 (en) 2005-05-04
US20080114009A1 (en) 2008-05-15
NO20026032D0 (no) 2002-12-16
CA2410232A1 (en) 2001-12-27
EP1296984A1 (en) 2003-04-02
HRP20020989B1 (hr) 2011-05-31
AU2001263962B2 (en) 2006-07-20
MXPA02012845A (es) 2003-05-15
CZ2003114A3 (cs) 2003-05-14
AU6396201A (en) 2002-01-02
KR100846370B1 (ko) 2008-07-15
AR030704A1 (es) 2003-09-03
ATE294804T1 (de) 2005-05-15
CZ295278B6 (cs) 2005-06-15
AU2006220405A1 (en) 2006-10-12
HUP0300872A3 (en) 2004-11-29
KR20030009463A (ko) 2003-01-29
US8318753B2 (en) 2012-11-27
MY127734A (en) 2006-12-29
CN1437601A (zh) 2003-08-20
CN1207296C (zh) 2005-06-22
BRPI0111743B1 (pt) 2019-03-26
IS2596B (is) 2010-03-15
US20070259902A1 (en) 2007-11-08
BRPI0111743B8 (pt) 2021-05-25
KR20070121847A (ko) 2007-12-27
PL358918A1 (en) 2004-08-23
JP2004501153A (ja) 2004-01-15
DE60110592T2 (de) 2006-01-19
EA005065B1 (ru) 2004-10-28
NZ522481A (en) 2004-09-24
DE60110592D1 (de) 2005-06-09
EG24180A (en) 2008-09-28
BG107310A (bg) 2003-07-31
HU229095B1 (en) 2013-07-29
EA200300048A1 (ru) 2003-04-24
SK502003A3 (en) 2003-05-02
PL209521B1 (pl) 2011-09-30
KR100831940B1 (ko) 2008-05-23
PA8519501A1 (es) 2002-08-29
CA2410232C (en) 2008-10-07
AU2006220405B2 (en) 2009-05-21
EE200200695A (et) 2004-06-15
BG65894B1 (bg) 2010-04-30
IL153560A0 (en) 2003-07-06
NO324494B1 (no) 2007-10-29
JO2361B1 (en) 2006-12-12
ZA200210305B (en) 2004-03-19
JP4919575B2 (ja) 2012-04-18
NO20026032L (no) 2002-12-16
HRP20020989A2 (en) 2005-02-28
US8329714B2 (en) 2012-12-11
WO2001098302A1 (en) 2001-12-27
UA73572C2 (en) 2005-08-15
SK285699B6 (sk) 2007-06-07
IL153560A (en) 2011-06-30
US20030114471A1 (en) 2003-06-19
EE04966B1 (et) 2008-02-15
SA01220349B1 (ar) 2007-01-23

Similar Documents

Publication Publication Date Title
ES2313991T3 (es) Derivados de 6-heterociclilmetil-quinolina y quinazolina que inhiben la farnesil transferasa.
ES2200591T3 (es) Derivados de 1,2-quinolina anelados.
US8318753B2 (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
JP2022524191A (ja) 大環状化合物
ES2287466T3 (es) Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa.
AU2001263962A1 (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
CN113350347B (zh) 吲唑类化合物的用途
AU2018447240B2 (en) Indazole kinase inhibitor and use thereof
CN110283160B (zh) 一种pdgfr激酶抑制剂
ES2323265T3 (es) Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa.
EP3896059A1 (en) Pan-kit kinase inhibitor having quinoline structure and application thereof
ES2271574T3 (es) Derivados triciclicos de quinazolina inhibidores de la farnesiltransferasa, sustituidos con imidazoles o triazoles enlazados al carbono.